Changes in body composition in men and women with advanced nonsmall cell lung cancer (NSCLC) undergoing chemotherapy

被引:20
|
作者
Harvie, MN
Campbell, IT
Thatcher, N
Baildam, A
机构
[1] S Manchester Univ Hosp NHS Trust, Univ Dept Anaesthesia, Manchester M20 2LR, Lancs, England
[2] S Manchester Univ Hosp NHS Trust, Univ Med Oncol, Manchester M20 2LR, Lancs, England
[3] S Manchester Univ Hosp NHS Trust, Univ Surg, Manchester M20 2LR, Lancs, England
关键词
body composition; dietary intake; energy expenditure; gender; nonsmall cell lung cancer; resting;
D O I
10.1046/j.1365-277X.2003.00459.x
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Background Men with nonsmall cell lung cancer (NSCLC) are more susceptible to weight loss than women. The composition and aetiology of these gender specific weight changes are not known. Methods Measurements of body mass, body composition and energy balance (resting energy expenditure and energy intake) were made in 15 men and six women before and after chemotherapy for NSCLC. Results Over the course of chemotherapy minimal weight change was observed in both men and women. Men increased body fat from 25.0 +/- 5.5 to 27.9 +/- 7.9% (P < 0.05) whereas fat free mass (FFM) tended to decrease (P = 0.063). There was no change in body fat or FFM in the women. In the men resting energy expenditure decreased over the course of chemotherapy from 113.2 +/- 15.9 to 105.1 +/- 10.1% of the value predicted from the Harris Benedict equation (P < 0.05). In the women resting energy expenditure (REE) did not alter. Conclusion Over the course of chemotherapy for NSCLC, men and women appear to have different patterns of change in body composition and in energy expenditure.
引用
收藏
页码:323 / 326
页数:4
相关论文
共 50 条
  • [1] PALLIATIVE CHEMOTHERAPY FOR ADVANCED NONSMALL CELL LUNG-CANCER
    SMITH, IE
    BRITISH MEDICAL JOURNAL, 1994, 308 (6926): : 429 - 430
  • [2] The role of maintenance chemotherapy in advanced nonsmall cell lung cancer
    Jalal, Shadia I.
    Ademuyiwa, Foluso O.
    Hanna, Nasser H.
    CURRENT OPINION IN ONCOLOGY, 2009, 21 (02) : 110 - 115
  • [3] CONCURRENT CHEMOTHERAPY (CT) AND RADIOTHERAPY (RT) IN LOCALLY ADVANCED NONSMALL CELL LUNG-CANCER (NSCLC) - A REVIEW
    MIRIMANOFF, RO
    LUNG CANCER, 1994, 11 : S79 - S99
  • [4] Current clinical immunotherapy targets in advanced nonsmall cell lung cancer (NSCLC)
    McCarthy, Fiona
    Roshani, Rozita
    Steele, Jeremy
    Hagemann, Thorsten
    JOURNAL OF LEUKOCYTE BIOLOGY, 2013, 94 (06) : 1201 - 1206
  • [5] The relationship between lung function and nonsmall cell lung cancer in men and women
    Malhotra, S
    Lam, S
    Man, SFP
    Gan, WQ
    Sin, DD
    CHEST, 2005, 128 (04) : 169S - 170S
  • [6] Chemotherapy in advanced nonsmall cell lung cancer: indication, intensity, and duration
    Booton, R
    Thatcher, N
    CURRENT OPINION IN ONCOLOGY, 2002, 14 (02) : 191 - 198
  • [7] NEOADJUVANT CHEMOTHERAPY OF LOCALLY ADVANCED NONSMALL CELL LUNG-CANCER
    PUJOL, JL
    LECHEVALIER, T
    RAY, P
    GAUTIER, V
    ROUANET, P
    ARRIAGADA, R
    GRUNENWALD, D
    MICHEL, FB
    LUNG CANCER, 1995, 12 : S107 - S118
  • [8] PREOPERATIVE CHEMOTHERAPY FOR LOCALLY ADVANCED NONSMALL CELL LUNG-CANCER
    HOLMES, EC
    RUCKDESCHEL, JC
    SEMINARS IN ONCOLOGY, 1994, 21 (03) : 97 - 100
  • [9] FDG-PET for staging of advanced nonsmall cell lung cancer (NSCLC) prior to neoadjuvant radio-chemotherapy.
    Eschmann, SM
    Friedel, G
    Dohmen, BM
    Budach, W
    Paulsen, F
    Dittmann, H
    Bares, R
    JOURNAL OF NUCLEAR MEDICINE, 2001, 42 (05) : 150P - 150P
  • [10] SCHEDULING OF CHEMOTHERAPY AND RADIOTHERAPY IN LOCALLY ADVANCED NONSMALL CELL LUNG-CANCER
    BISHOP, JF
    LUNG CANCER, 1995, 12 : S53 - S61